Portage Biotech Inc. Stock News

WESTPORT, Conn., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and

FYBR, SPPJY, KMTUY, PRTG and ASML have been added to the Zacks Rank #1 (Strong Buy) List on January 26, 2023.

NBSE, PRTG, RELL, HOWL and PATH have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2022.

FFNW, PTEN, PRTG, NTNX and GAMB have been added to the Zacks Rank #1 (Strong Buy) List on November 1, 2022.

The mean of analysts' price targets for Portage Biotech Inc. (PRTG) points to a 206.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement

Portage Biotech Inc (NASDAQ: PRTG) acquired the remaining 22% stake in its invariant natural killer T cell (iNKT agonist) platform and now wholly owns the worldwide rights to its small molecule iNK

Portage Biotech Inc (PRTG) shares closed today 11.8% higher than it did at the end of yesterday. The stock is currently up 11.8% year-to-date, up 6757.1% over the past 12 months, and up 6757.1% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $12.10 and as low as $10.52 this week.Shares closed 73.3% below its 52-week high and 14.1% above its 52-week low.Trading volume this week was 7.4% higher than the 10-day average and 15.0% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, beats it on a 1-year basis, and beats it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 2592.8% The company's stock price performance over the past 12 months beats the peer average by -56778.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Portage Biotech Inc (PRTG) shares closed this week 20.8% lower than it did at the end of last week. The stock is currently up 9208.6% year-to-date, up 9208.6% over the past 12 months, and up 9208.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 0.1%. Trading Activity Shares traded as high as $23.55 and as low as $15.83 this week.Trading volume this week was 59.3% higher than the 10-day average and 131.4% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index this week, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, beats it on a 1-year basis, and beats it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -101669.4% The company's stock price performance over the past 12 months beats the peer average by -83907.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

WESTPORT, Conn., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve pa

WESTPORT, Conn., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company focused on the development of the

- $29 million raised during quarter with broad institutional support

WESTPORT, Conn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of ther

Westport, Connecticut--(Newsfile Corp. - June 29, 2021) - Portage Biotech Inc., (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of thera

Westport, Connecticut--(Newsfile Corp. - June 24, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therap

Westport, Connecticut--(Newsfile Corp. - June 23, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therap